GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kancera AB (OSTO:KAN) » Definitions » Net Margin %

Kancera AB (OSTO:KAN) Net Margin % : 0.00% (As of Sep. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Kancera AB Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Kancera AB's Net Income for the three months ended in Sep. 2023 was kr-10.73 Mil. Kancera AB's Revenue for the three months ended in Sep. 2023 was kr0.00 Mil. Therefore, Kancera AB's net margin for the quarter that ended in Sep. 2023 was 0.00%.

The historical rank and industry rank for Kancera AB's Net Margin % or its related term are showing as below:

OSTO:KAN' s Net Margin % Range Over the Past 10 Years
Min: -49732.74   Med: -5177.2   Max: -409.16
Current: -9762.84


OSTO:KAN's Net Margin % is ranked worse than
90.38% of 1029 companies
in the Biotechnology industry
Industry Median: -157.22 vs OSTO:KAN: -9762.84

Kancera AB Net Margin % Historical Data

The historical data trend for Kancera AB's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kancera AB Net Margin % Chart

Kancera AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12,831.01 -1,122.36 -752.09 -2,681.10 -6,969.99

Kancera AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,955.91 -51,892.59 -12,866.91 -3,988.82 -

Competitive Comparison of Kancera AB's Net Margin %

For the Biotechnology subindustry, Kancera AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kancera AB's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kancera AB's Net Margin % distribution charts can be found below:

* The bar in red indicates where Kancera AB's Net Margin % falls into.



Kancera AB Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Kancera AB's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin=Net Income (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-52.484/0.753
=-6,969.99 %

Kancera AB's Net Margin for the quarter that ended in Sep. 2023 is calculated as

Net Margin=Net Income (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-10.733/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kancera AB  (OSTO:KAN) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Kancera AB Net Margin % Related Terms

Thank you for viewing the detailed overview of Kancera AB's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kancera AB (OSTO:KAN) Business Description

Traded in Other Exchanges
Address
Karolinska Institutet Science Park, Banvaktsvagen 22, Solna, SWE, 171 48
Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and KAND145 are developed to effectively counteract hyperinflamation in various disease states and thereby protect vital organs in conjunction with myocardial infarction and severe viral infections. Kancera is planning two phase II clinical trials, in covid-19 and in cardiac patients. The company conducts research and development within the Karolinska Institute Science Park in Stockholm.

Kancera AB (OSTO:KAN) Headlines

No Headlines